VIE News
Archived Headlines
- Biotech boom: 6 biotechs are in line to go public starting next week 09/26/19
- Autoimmune biotech Viela Bio sets terms for $150 million IPO 09/23/19
- US IPO Weekly Recap: Peloton Interactive enters the pipeline as summer wraps up 08/30/19
- Autoimmune biotech Viela Bio files for a $150 million IPO 08/29/19
US IPO Weekly Recap: Oncology biotech Aprea Therapeutics finishes on top in 4-IPO week
Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price IPOs this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or...read more
Autoimmune biotech Viela Bio prices IPO at the $19 low end
Viela Bio, a late-stage biotech developing antibodies licensed from AstraZeneca, raised $150 million by offering 7.9 million shares at $19, the low end of the range of $19 to $21. The company sold an additional 400,000 shares to maintain the original deal size....read more
5 biotech IPOs are pricing tonight with 2 more on the calendar
After a wave of biotech launches last week, one more filed terms this week. Seven biotechs are currently on the Renaissance IPO calendar, four of which are targeting billion-dollar valuations. Five are set to price tonight. Swiss biotech ...read more
US IPO Week Ahead: A wave of biotechs and billion-dollar valuations in 6-IPO week
Six IPOs plan to raise $596 million in the week ahead, with two biotechs targeting billion-dollar-plus valuations. Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million at a $1.8 billion valuation. Insiders have indicated on...read more